Journal article
Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.
Abstract
BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI), early initiation of high-intensity statin therapy, regardless of low-density lipoprotein (LDL) cholesterol levels, is the standard of practice worldwide. Aims: We sought to determine the effect of a similar early initiation strategy, using a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor added to the high-intensity statin, on LDL cholesterol in …
Authors
Mehta SR; Pare G; Lonn EM; Jolly SS; Natarajan MK; Pinilla-Echeverri N; Schwalm J-D; Sheth TN; Sibbald M; Tsang M
Journal
EuroIntervention, Vol. 18, No. 11, pp. e888–e896
Publisher
Europa Digital & Publishing
DOI
10.4244/eij-d-22-00735
ISSN
1774-024X